Publications - 'P'
Publications 676 - 700 de 2458
| Titre | DOI |
|---|---|
|
Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol J. Le Guevelou; C. Debaigt; E. Saada-Bouzid; J. Viotti; N. Khalladi; D. Thibouw; N. Penel; M.Pierre Sunyach; L. Moureau-Zabotto; M. Benchalal; O. Veresezan; A. Ducassou; C. Le Pechoux; M. Jolnerovski; C. Bazille; D. Vaur; A. Escande; R. Serre; C. Lovera; J. Thariat 2020 |
10.1136/bmjopen-2020-038391 |
|
Phase II study of neoadjuvant `supercastration' in men with high-risk prostate cancer N. Corcoran; N. Howard; P. Bugeja; M. Kerger; D. Moon; D. Clarke; J. Grummet; C. Hovens; T. Costello; J. Pedersen; A. Ryan; P. Ruljancich; P. Parente 2014 |
|
|
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas E. Maubec; M. Boubaya; P. Petrow; M. Beylot-Barry; N. Basset-Seguin; L. Deschamps; J.J. Grob; B. Dreno; I. Scheer-Senyarich; C. Bloch-Queyrat; M.T. Leccia; A. Stefan; P. Saiag; F. Grange; N. Meyer; J. De Quatrebarbes; M. Dinulescu; D. Legoupil; L. Machet; O. Dereure; O. Zehou; H. Montaudie; E. Wierzbicka-Hainaut; Y. Le Corre; S. Mansard; S. Guegan; J.P. Arnault; S. Dalac; F. Aubin; C. Alloux; I. Lopez; S. Cherbal; A. Tibi; V. Levy; G.Cancerolog Cutanee 2020 |
10.1200/JCO.19.03357 |
|
Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group P.E. Heudel; M. Fabbro; C. Roemer-Becuwe; M.C. Kaminsky; A. Arnaud; F. Joly; S. Roche-Forestier; J. Meunier; C. Foa; B. You; F. Priou; Y. Tazi; A. Floquet; F. Selle; D. Berton-Rigaud; A. Lesoin; E. Kalbacher; A. Lortholary; L. Favier; I. Treilleux; I. Ray-Coquard 2017 |
10.1038/bjc.2016.430 |
|
Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics G.J.L. Kaspers; D. Niewerth; B. Wilhelm; S. Ramnarain; H. Berkhof; V. de Haas; R.A.A. Mathot; A. Attarbaschi; A. Baruchel; E.S. de Bont; F. Fagioli; C. Rossig; T. Klingebiel; B. De Moerloose; B. Nelken; G. Palumbo; D. Reinhardt; P.Simon Rohrlich; P. Simon; A. Stackelberg; M. Zwaan 2015 |
|
|
Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404-REGOLD T. Aparicio; D. Jouve; F. Khemissa; C. Monterymard; P. Artru; L. Cany; O. Romano; B. Valenza; C. Le Foll; C. Delbaldo; C. Falandry; M. Duluc; Y. Rinaldi; J.L. Legoux; M. Ben Abdelghani; E. Assenat; M. Dhooge; D. Smith; D. Guetz; C. Lepage 2018 |
|
|
Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404-REGOLD T. Aparicio; D. Jouve; F. Khemissa; C. Monterymard; P. Artru; L. Cany; O. Romano; B. Valenza; C. Le Foll; C. Delbaldo; C. Falandry; M. Duluc; Y. Rinaldi; J.L. Legoux; M. Ben Abdelghani; E. Assenat; M. Dhooge; D. Smith; D. Guetz; C. Lepage 2018 |
|
|
Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404-REGOLD T. Aparicio; D. Jouve; F. Khemissa; C. Monterymard; P. Artru; L. Cany; O. Romano; B. Valenza; C. Le Foll; C. Delbaldo; C. Falandry; M. Duluc; Y. Rinaldi; J.L. Legoux; M. Ben Abdelghani; E. Assenat; M. Dhooge; D. Smith; D. Guetz; C. Lepage 2018 |
|
|
Phase II/III randomized trial of exclusive chemoradiotherapy with or without dose escalation in locally advanced esophageal carcinoma: The CONCORDE study (PRODIGE 26). G. Crehange; F. Bonnetain; D. Peiffert; E. Le Prise; P.L. Etienne; E. Rio; R. Pereira; G. Noel; K. Benezery; J.Francois Seitz 2016 |
10.1200/jco.2016.34.4_suppl.tps190 |
|
Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status C. Jackisch; R. Hegg; D. Stroyakovskiy; J.S. Ahn; B. Melichar; S.C. Chen; A. Crepelle-Flechais; S. Lauer; M. Shing; X. Pivot 2015 |
10.1016/S0959-8049(16)30893-0 |
|
Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status J.S. Ahn; C. Jackisch; R. Hegg; D. Stroyakovskiy; B. Melichar; S.C. Chen; A. Crepelle-Flechais; S. Lauer; M. Shing; X. Pivot 2015 |
|
|
Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study) A. Zaanan; E. Samalin; T. Aparicio; O. Bouche; P. Laurent-Puig; S. Manfredi; P. Michel; C. Monterymardi; M. Moreau; P. Rougier; D. Tougeron; J. Taieb; C. Louvet 2018 |
10.1016/j.dld.2018.01.119 |
|
Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients M. Shing; K.H. Jung; B. Ataseven; M. Verrill; M. De Laurentiis; H.A. Azim; X. Pivot; N. Al-Sakaff; S. Lauer; J. Gligorov 2015 |
|
|
Phase III SafeHer study subgroup analyses: Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients M. Shing; K.H. Jung; B. Ataseven; M. Verrill; M. De Laurentiis; H.A. Azim; X. Pivot; N. Al-Sakaff; S. Lauer; J. Gligorov 2015 |
|
|
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1 M. Smith; J. de Bono; C. Sternberg; S. Le Moulec; S. Oudard; U. De Giorgi; M. Krainer; A. Bergman; W. Hoelzer; R. De Wit; M. Boegemann; F. Saad; G. Cruciani; A. Thiery-Vuillemin; S. Feyerabend; K. Miller; N. Houede; S. Hussain; E. Lam; J. Polikoff; A. Stenzl; P. Mainwaring; D. Ramies; C. Hessel; A. Weitzman; K. Fizazi 2016 |
10.1200/JCO.2015.65.5597 |
|
Phase III study of ribociclib (LEE011) in combination with fulvestrant for the treatment of postmenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC) who have received no or only one line of pri P.A. Fasching; G. Jerusalem; X. Pivot; M. Martin; M. De Laurentiis; K. Blackwell; F.J. Esteva; T. Paquet-Luzy; Z. Tang; K.R. Lorenc; D.J. Slamon 2016 |
10.1158/1538-7445.SABCS15-OT2-01-02 |
|
Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7) A. Bredart; A. Anota; T. Young; K.A. Tomaszewski; J.I. Arraras; M.De Albuque Melo; H. Schmidt; E. Friend; M. Bergenmar; A. Costantini; V. Vassiliou; J. Hureaux; F. Marchal; I.M. Tomaszewska; W.C. Chie; J. Ramage; A. Beaudeau; T. Conroy; E. Bleiker; D. Kulis; F. Bonnetain; N.K. Aaronson; E.O.R.T.C.Quality Li Grp 2018 |
10.1111/ecc.12786 |
|
Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs. trastuzumab plus taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE. E.A. Perez; C.H. Barrios; W. Eiermann; M. Toi; Y.H. Im; P.Franco Conte; M. Martin; T. Pienkowski; X.B. Pivot; H.A. Burris; S. Hoersch; M. Patre; P.Anthony Ellis 2017 |
10.1200/JCO.2017.35.15_suppl.1003 |
|
Phase III, randomized study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab plus taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. P.Anthony Ellis; C.H. Barrios; W. Eiermann; M. Toi; Y.H. Im; P.Franco Conte; M. Martin; T. Pienkowski; X.B. Pivot; H.A. Burris; A. Strasak; M. Patre; E.A. Perez 2015 |
10.1200/jco.2015.33.15_suppl.507 |
|
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early X. Pivot; I. Bondarenko; Z. Nowecki; M. Dvorkin; E. Trishkina; J.H. Ahn; Y. Vinnyk; S.A. Im; T. Sarosiek; S. Chatterjee; M.Z. Wojtukiewicz; V. Moiseyenko; Y. Shparyk; ; V. Semiglazov; S. Song; J. Lim 2018 |
10.1200/JCO.2017.74.0126 |
|
Phase Noise and Frequency Stability of the Red-Pitaya Internal PLL A.Carolina C. Olaya; C.Eligio Calosso; J.M. Friedt; S. Micalizio; E. Rubiola 2019 |
10.1109/TUFFC.2018.2883830 |
|
Phase noise measurement: Challenges and uncertainty A.K. Poddar; U.L. Rohde; E. Rubiola 2014 |
|
|
Phase Noise Measurements of AlN Contour-Mode Resonators With Carrier Suppression Technique E. Vaillant; F. Sthal; J. Imbaud; V. Soumann; P. Abbe; L. Arapan; F.X. Esnault; G. Cibiel; J. Segovia-Fernandez; G. Piazza 2018 |
10.1109/TUFFC.2018.2850223 |
|
Phase Noise Measurements of Surface Acoustic Wave Resonators at 2.4 GHz E. Vaillant; J. Imbaud; F. Sthal; F.X. Esnault; G. Cibiel 2017 |
|
|
Phase Noise Measurements of Surface Acoustic Wave Resonators at 2.4 GHz E. Vaillant; J. Imbaud; F. Sthal; F.X. Esnault; G. Cibiel 2017 |